Related Experiment Video

Updated: Jul 20, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

The management of pediatric systemic lupus erythematosus

Stacy P Ardoin1, Laura E Schanberg

  • 1Division of Pediatric Rheumatology, Duke University Medical Center, Durham, NC 27710, USA.

Nature Clinical Practice. Rheumatology
|August 26, 2006
PubMed

Insights

Pediatric systemic lupus erythematosus (SLE) survivors need specialized care to prevent long-term issues like atherosclerosis. More research is crucial to understand and treat this unique childhood autoimmune disease effectively.

Area of Science:

  • Pediatric Rheumatology
  • Autoimmune Diseases
  • Systemic Lupus Erythematosus (SLE)

Background:

  • Most children and adolescents with SLE now survive into adulthood.
  • Focus is shifting to preventing long-term complications such as atherosclerosis, obesity, and osteoporosis.
  • Significant knowledge gaps exist regarding pediatric SLE epidemiology, outcomes, and optimal treatment.

Purpose of the Study:

  • To highlight the distinct characteristics of pediatric SLE compared to adult SLE.
  • To emphasize the need for specialized, multidisciplinary care for children and adolescents with SLE.
  • To underscore the necessity for targeted research in pediatric SLE.

Main Methods:

  • Review of current understanding and challenges in pediatric SLE management.
  • Identification of key areas requiring further investigation.
  • Discussion of essential components for optimizing treatment and care.

Main Results:

  • Pediatric SLE differs significantly from adult SLE in disease expression, treatment, and psychosocial aspects.
  • Optimizing treatment involves early recognition of flares/complications, minimizing toxicity, and addressing developmental concerns.
  • Transition to adult care and research into developmental immunology are critical.

Conclusions:

  • Children and adolescents with SLE require specialized, multidisciplinary care.
  • Addressing developmental, psychosocial, and transition issues is vital for successful management.
  • Urgent research is needed to improve understanding and treatment of pediatric SLE.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...